Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia

Bláha, M.; Cermanová, Melánie; Bláha, V.; Jarolím, Petr; Andrýs, Ctirad; Błażek, M.; Malý, J; Smolej, Lukáš; J, Zajíc; Mašín, Vladimír; Zimová, R.; Řeháček, Vít

doi:10.1016/j.atherosclerosis.2007.04.022

Cited by 36 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In humans, Blaha et al 15 demonstrated serum sEng levels to be high in 11 patients with familial hypercholesterolemia and to decrease after extracorporeal LDL cholesterol elimination. Blázquez-Medela et al 16 measured plasma sEng levels in 64 diabetic patients, 159 hypertensive patients, and 65 healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis—Brief Report

Saita

Miura

Suzuki-Sugihara

et al. 2017

ATVB

View full text Add to dashboard Cite

Objective-Transforming growth factor-β inhibits migration and proliferation of endothelial and smooth muscle cells.Endoglin is a transmembrane receptor for transforming growth factor-β1 and transforming growth factor-β3. Endoglin is released into blood as a soluble form (soluble endoglin [sEng]), but plasma sEng levels in patients with coronary artery disease (CAD) have not been elucidated. Approach and Results-We measured plasma sEng levels in 244 patients undergoing coronary angiography. The severity of coronary atherosclerosis was evaluated as the numbers of >50% stenotic vessels and segments. CAD was found in 147 patients, of whom 55 had 1-vessel, 42 had 2-vessel, and 50 had 3-vessel disease. Compared with 97 patients without CAD, 147 with CAD had lower sEng levels (median 4.04 versus 4.37 ng/mL; P<0.005). A stepwise decrease in sEng levels was found based on the number of stenotic vessels: 4.37 in CAD(−), 4.23 in 1-vessel, 4.13 in 2-vessel, and 3.74 ng/mL in 3-vessel disease (P<0.005). sEng levels inversely correlated with the number of stenotic segments (r=−0.25; P<0.001). In multivariate analysis, sEng was an independent factor for 3-vessel disease and CAD. Odds ratios for CAD and 3-vessel disease were 0.97 (95% confidence interval, 0.95-0.99; P<0.02) and 0.96 (95% confidence interval, 0.93-0.99; P<0.01) for a 0.1 ng/mL increase in sEng levels, respectively. Conclusions-Plasma sEng levels were low in patients with CAD, especially 3-vessel disease, and were inversely associated with the severity of coronary atherosclerosis. The study sponsors had no role in the design, analysis, and interpretation of the study. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis—Brief Report

Saita

Miura

Suzuki-Sugihara

et al. 2017

ATVB

View full text Add to dashboard Cite

show abstract

“…Since it was demonstrated that endoglin may be released from the cellular membrane into the circulation as soluble endoglin, 42 and that serum endoglin levels are elevated in atherosclerosis, 23 we also evaluated the levels of endoglin in blood serum. Results of this current study revealed a significant increase in the endoglin serum levels in mice fed a cholesterol-rich diet when compared to mice fed chow diet only.…”

Section: Discussionmentioning

confidence: 99%

Cholesterol Effects on Endoglin and Its Downstream Pathways in ApoE/LDLR Double Knockout Mice

Strasky

Vecerova

Rathouska

et al. 2011

Circ J

Self Cite

View full text Add to dashboard Cite

“…50 Data from one patient, however, suggested that DSC apheresis does not reduce endothelin-1 but modestly reduces circulating soluble endoglin (online-only Data Supplement Table III), similar to what has been reported in patients with FH. 51 The specificity of sFlt-1 removal may be improved by developing extracorporeal columns with anti-sFlt-1 antibodies covalently bound to beads, similar to methods developed in LDL apheresis. 52 Such specificity may reduce the frequency of treatments when compared to the 1 to 2 treatments/ week we employed to avert further elevations in circulating sFlt-1 levels.…”

Section: Thadhani Et Al Sflt-1 Removal In Preeclampsia 947mentioning

confidence: 99%

Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia

et al. 2011

View full text Add to dashboard Cite

Background-Targeted therapies to stabilize the clinical manifestations and prolong pregnancy in preeclampsia do not exist. Soluble fms-like tyrosine kinase 1 (sFlt-1), an alternatively spliced variant of the vascular endothelial growth factor receptor 1, induces a preeclampsia-like phenotype in experimental models and circulates at elevated levels in human preeclampsia. Removing sFlt-1 may benefit women with very preterm (Ͻ32 weeks) preeclampsia. Methods and Results-We first show that negatively charged dextran sulfate cellulose columns adsorb sFlt-1 in vitro. In 5 women with very preterm preeclampsia and elevated circulating sFlt-1 levels, we next demonstrate that a single dextran sulfate cellulose apheresis treatment reduces circulating sFlt-1 levels in a dose-dependent fashion. Finally, we performed multiple apheresis treatments in 3 additional women with very preterm (gestational age at admission 28, 30, and 27ϩ4 weeks) preeclampsia and elevated circulating sFlt-1 levels. Dextran sulfate apheresis lowered circulating sFlt-1, reduced proteinuria, and stabilized blood pressure without apparent adverse events to mother and fetus. Pregnancy lasted for 15 and 19 days in women treated twice and 23 days in a woman treated 4 times. In each, there was evidence of fetal growth. Conclusions-This pilot study supports the hypothesis that extracorporeal apheresis can lower circulating sFlt-1 in very preterm preeclampsia. Further studies are warranted to determine whether this intervention safely and effectively prolongs pregnancy and improves maternal and fetal outcomes in this setting. (Circulation. 2011;124:940-950.)Key Words: angiogenic factor Ⅲ apheresis Ⅲ preeclampsia P reeclampsia is a devastating medical complication of pregnancy associated with significant maternal and fetal morbidity and mortality. 1 The risk is highest in very preterm (Ͻ32 weeks) preeclampsia when the infant mortality rate is 70 times higher than at term. 2,3 Delivery of the placenta remains the only effective means to treat preeclampsia. Randomized trials have tested nonspecific interventions including antihypertensive agents; however, the ability of these and other interventions to prevent or stabilize the clinical manifestations and prolong pregnancy in preterm preeclampsia is limited. 4 -6 The underlying pathogenesis of preeclampsia has remained elusive, hampering successful development of targeted interventions for the condition. Clinical Perspective on p 950The prevailing hypothesis suggests that preeclampsia involves a placental factor that circulates to distal organs and causes damage to the vasculature. 7 We and others have suggested that excess placental derived soluble fms-like tyrosine kinase 1 (sFlt-1) or the soluble vascular endothelial growth factor (VEGF) receptor 1, an alternatively spliced variant of VEGF receptor 1, mediates the signs and symptoms of preeclampsia, and elevated circulating levels are associated with clinical preeclampsia. 8 -11 Circulating sFlt-1 levels in very preterm preeclampsia are among the highest obs...

show abstract

Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia

Cited by 36 publications

References 22 publications

Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis—Brief Report

Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis—Brief Report

Cholesterol Effects on Endoglin and Its Downstream Pathways in ApoE/LDLR Double Knockout Mice

Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia

Contact Info

Product

Resources

About